Biogen Inc. (NASDAQ:BIIB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Biogen Inc. (NASDAQ:BIIB) have been given a consensus recommendation of “Moderate Buy” by the thirty-one analysts that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation, sixteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $218.2222.

A number of equities analysts have recently issued reports on BIIB shares. Truist Financial dropped their price target on Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a research note on Monday, April 13th. Zacks Research lowered shares of Biogen from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Canaccord Genuity Group lifted their price target on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a research note on Monday, June 22nd. Finally, Wall Street Zen upgraded shares of Biogen from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd.

Biogen Stock Up 1.3%

Shares of NASDAQ BIIB traded up $2.67 during midday trading on Thursday, hitting $211.13. The stock had a trading volume of 208,982 shares, compared to its average volume of 1,255,519. The business’s 50 day moving average is $197.02 and its 200-day moving average is $187.37. The company has a market cap of $31.17 billion, a P/E ratio of 22.66 and a beta of 0.16. Biogen has a 52 week low of $121.05 and a 52 week high of $219.72. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, analysts predict that Biogen will post 13.95 EPS for the current year.

Institutional Trading of Biogen

Institutional investors have recently made changes to their positions in the business. Rothschild Investment LLC boosted its stake in Biogen by 12.3% in the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 56 shares during the period. Meeder Advisory Services Inc. raised its position in shares of Biogen by 1.2% during the first quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after buying an additional 57 shares during the last quarter. Kera Capital Partners Inc. raised its position in shares of Biogen by 3.5% during the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 58 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of Biogen by 1.5% in the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after buying an additional 65 shares in the last quarter. Finally, Itau Unibanco Holding S.A. boosted its position in shares of Biogen by 24.4% during the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 66 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.